Ulrich Martin

– DAWNZERA demonstrated significant and sustained HAE attack rate reduction and long-term disease control – – Offers longest dosing option for HAE, with dosing every 4 or 8 weeks – – Compelling profile supported by recently published switch data – – Ionis’ second independent launch in just nine months, with potential for two additional launches next year – CARLSBAD, CA, USA I August 21, 2025 I Ionis Pharmaceuticals, Inc.

MELBOURNE, Australia I August 21, 2025 I SMSbiotech, a San Diego–based leader in regenerative medicine, today announced the initiation of its first-in-human Phase 1 clinical trial for Chronic Obstructive Pulmonary Disease (COPD). This milestone marks the transition of years of dedicated research into clinical development, with the goal of delivering a transformative therapy for millions living with this debilitating lung condition.

SANTA MONICA, CA & PHILADELPHIA, PA, USA I August 21, 2025 I Kite, a Gilead Company (Nasdaq: GILD), today announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million. This acquisition complements Kite’s expertise in cell therapy by incorporating Interius’s integrating in vivo platform.